Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Biofrontera (BFRI) over the last 6 years, with Q3 2025 value amounting to $6.6 million.

  • Biofrontera's Accounts Payables rose 4077.34% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 4077.34%. This contributed to the annual value of $4.3 million for FY2024, which is 476.93% down from last year.
  • Per Biofrontera's latest filing, its Accounts Payables stood at $6.6 million for Q3 2025, which was up 4077.34% from $5.8 million recorded in Q2 2025.
  • In the past 5 years, Biofrontera's Accounts Payables ranged from a high of $11.1 million in Q1 2023 and a low of $3.6 million during Q2 2024
  • Moreover, its 5-year median value for Accounts Payables was $7.5 million (2022), whereas its average is $7.3 million.
  • In the last 5 years, Biofrontera's Accounts Payables soared by 25676.27% in 2021 and then tumbled by 6201.17% in 2024.
  • Quarter analysis of 5 years shows Biofrontera's Accounts Payables stood at $9.7 million in 2021, then increased by 12.53% to $10.9 million in 2022, then crashed by 58.7% to $4.5 million in 2023, then dropped by 4.77% to $4.3 million in 2024, then soared by 53.36% to $6.6 million in 2025.
  • Its Accounts Payables was $6.6 million in Q3 2025, compared to $5.8 million in Q2 2025 and $4.6 million in Q1 2025.